β-Glycosphingolipids improve glucose intolerance and hepatic steatosis of the cohen diabetic rat

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 1, 2009, Pages

  Zigmond, Ehud ^a,e   Zangen, Sarah W ^b,e   Pappo, Orit ^c   Sklair Levy, Miriam ^d   Lalazar, Gadi ^a   Zolotaryova, Lydia ^a   Raz, Itamar ^b   Ilan, Yaron ^c  

^a Liver Unit   (Israel)

^b Diabetes Unit   (Israel)

^c Department of Pathology ^*  (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Glycolipids; Immune response; Natural killer t cells; Type 2 diabetes

Indexed keywords

BETA GLUCOSYLCERAMIDE; BETA LACTOSYLCERAMIDE; GLUCOSE; GLYCOSPHINGOLIPID; INSULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC DIET; FATTY LIVER; FLUORESCENCE ACTIVATED CELL SORTER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HISTOLOGY; IMMUNOMODULATION; INSULIN BLOOD LEVEL; LIVER; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; CD8-POSITIVE T-LYMPHOCYTES; FATTY LIVER; FLOW CYTOMETRY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLUCOSYLCERAMIDES; HISTOCYTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; LACTOSYLCERAMIDES; MAGNETIC RESONANCE IMAGING; MALE; RATS; TRIGLYCERIDES;

EID: 58249116770     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90634.2008     Document Type: Article

References (39)

1. Aerts JM, Ottenhoff R, Powlson AS, Grefhorst A, van Eijk M, Dubbelhuis PF, Aten J, Kuipers F, Serlie MJ, Wennekes T, Sethi JK, O'Rahilly S, Overkleeft HS. Pharmacological inhibition of glucosylcer-amide synthase enhances insulin sensitivity. Diabetes 56: 1341-1349, 2007.
2. Agrati C, Nisii C, Oliva A, D'Offizi G, Montesano C, Pucillo LP, Poccia F. Lymphocyte distribution and intrahepatic compartmentalization during HCV infection: a main role for MHC-unrestricted T cells. Arch Immunol Ther Exp (Warsz) 50: 307-316, 2002.
3. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 25: 297-336, 2007.
4. Bloomgarden ZT. Inflammation, atherosclerosis, and aspects of insulin action. Diabetes Care 28: 2312-2319, 2005.
5. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21: 3-16, 2001.
6. Brutkiewicz RR. CD1d ligands: the good, the bad, and the ugly. J Immunol 177: 769-775, 2006.
7. Buzas EI, Gyorgy B, Pasztoi M, Jelinek I, Falus A, Gabius HJ. Carbohydrate recognition systems in autoimmunity. Autoimmunity 39: 691-704, 2006.
8. Cohen AM. Development of the model. In: The Cohen Diabetic Rat, edited by Cohen A and Rosenmann E. Basel: Karger, 1990, p. 1-9.
9. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 3: 51-62, 2003.
10. Donath MY, Halban PA. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47: 581-589, 2004.
11. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet beta-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 81: 455-470, 2003.
12. + natural killer T cells mature dendritic cells, leading to strong adaptive immunity. Immunol Rev 220: 183-198, 2007.
13. Gumperz JE. CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? J Leukoc Biol 76: 307-313, 2004.
14. Hussain S, Wagner M, Ly D, Delovitch TL. Role of regulatory invariant CD1d-restricted natural killer T-cells in protection against type 1 diabetes. Immunol Res 31: 177-188, 2005.
15. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, Taniguchi M. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626 -1629, 1997.
16. Lalazar G, Ben Ya'acov A, Eliakim-Raz N, Livovsky DM, Pappo O, Preston S, Zolotarov L, Ilan Y. Beta-glycosphingolipids-mediated lipid raft alteration is associated with redistribution of NKT cells and increased intrahepatic CD8+ T lymphocyte trapping. J Lipid Res 49: 1884-1893, 2008.
17. Lalazar G, Ben Ya'acov A, Lador A, Livovsky DM, Pappo O, Preston S, Hareati M, Ilan Y. Modulation of intracellular machinery by beta-glycolipids is associated with alteration of NKT lipid rafts and amelioration of concanava-lin-induced hepatitis. Mol Immunol 45: 3517-3525, 2008.
18. Lalazar G, Preston S, Zigmond E, Ben Yaacov A, Ilan Y. Glycolipids as immune modulatory tools. Mini Rev Med Chem 6: 1249 -1253, 2006.
19. Ly D, Mi QS, Hussain S, Delovitch TL. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells. J Immunol 177: 3695-3704, 2006.
20. Margalit M, Ghazala SA, Alper R, Elinav E, Klein A, Doviner V, Sherman Y, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. Glucocere-broside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 289: G917-G925, 2005.
21. Margalit M, Shalev Z, Pappo O, Sklair-Levy M, Alper R, Gomori M, Engelhardt D, Rabbani E, Ilan Y. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J Pharmacol Exp Ther 319: 105-110, 2006.
22. Mars LT, Novak J, Liblau RS, Lehuen A. Therapeutic manipulation of iNKT cells in autoimmunity: modes of action and potential risks. Trends Immunol 25: 471-476, 2004.
23. Mitchell DG, Kim I, Chang TS, Vinitski S, Consigny PM, Saponaro SA, Ehrlich SM, Rifkin MD, Rubin R. Fatty liver. Chemical shift phase-difference and suppression magnetic resonance imaging techniques in animals, phantoms, and humans. Invest Radiol 26: 1041-1052, 1991.
24. Namimoto T, Yamashita Y, Mitsuzaki K, Nakayama Y, Makita O, Kadota M, Takahashi M. Adrenal masses: quantification of fat content with double-echo chemical shift in-phase and opposed-phase FLASH MR images for differentiation of adrenal adenomas. Radiology 218: 642-646, 2001.
25. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 41: 1241-1248, 1998.
26. Sharif S, Arreaza GA, Zucker P, Delovitch TL. Regulatory natural killer T cells protect against spontaneous and recurrent type 1 diabetes. Ann NY Acad Sci 958: 77-88, 2002.
27. Shibolet O, Alper R, Zolotarov L, Trop S, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y. The role of intrahepatic CD8+ T cell trapping and NK1.1+ cells in liver-mediated immune regulation. Clin Immunol 111: 82-92, 2004.
28. Stanic AK, De Silva AD, Park JJ, Sriram V, Ichikawa S, Hirabyashi Y, Hayakawa K, Van Kaer L, Brutkiewicz RR, Joyce S. Defective presentation of the CD1d1-restricted natural Va14Ja18 NKT lymphocyte antigen caused by beta-D-glucosylceramide synthase deficiency. Proc Natl Acad Sci USA 100: 1849-1854, 2003.
29. Stanic AK, Park JJ, Joyce S. Innate self recognition by an invariant, rearranged T-cell receptor and its immune consequences. Immunology 109: 171-184, 2003.
30. Stanic AK, Shashidharamurthy R, Bezbradica JS, Matsuki N, Yo-shimura Y, Miyake S, Choi EY, Schell TD, Van Kaer L, Tevethia SS, Roopenian DC, Yamamura T, Joyce S. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor. J Immunol 171: 4539-4551, 2003.
31. Tagami S, Inokuchi Ji J, Kabayama K, Yoshimura H, Kitamura F, Uemura S, Ogawa C, Ishii A, Saito M, Ohtsuka Y, Sakaue S, Igarashi Y. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J Biol Chem 277: 3085-3092, 2002.
32. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27: 223-228, 2004.
33. Tupin E, Kinjo Y, Kronenberg M. The unique role of natural killer T cells in the response to microorganisms. Nat Rev Microbiol 5: 405-417, 2007.
34. Weksler-Zangen S, Raz I, Lenzen S, Jorns A, Ehrenfeld S, Amir G, Oprescu A, Yagil Y, Yagil C, Zangen DH, Kaiser N. Impaired glucose stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes 57: 279-287, 2008.
35. Weksler-Zangen S, Yagil C, Zangen DH, Ornoy A, Jacob HJ, Yagil Y. The newly inbred Cohen diabetic rat: a nonobese normolipidemic genetic model of diet-induced type 2 diabetes expressing sex differences. Diabetes 50: 2521-2529, 2001.
36. Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 54: 1487-1496, 2005.
37. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56: 1210-1218, 2007.
38. Zigmond E, Papo O, Zangen S, Levy Sklair M, Hemed N, Rabbani E, Itamar R, Ilan Y, Margalit M. Treatment of non-alcoholic steatohepatitis by β-glucosylceramide: a phase I/II clinical study (Abstract). Hepatology 44: 180A, 2006.
39. Zigmond E, Preston S, Pappo O, Lalazar G, Margalit M, Shalev Z, Zolotarov L, Friedman D, Alper R, Ilan Y. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphocyte plasticity in murine models of immune-mediated disorders. Gut 56: 82-89, 2007.